Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 18, 2026

Stocks Climb on Solid US Economic News and Easing AI Jitters

View original at nasdaq.com
Stocks Climb on Solid US Economic News and Easing AI Jitters The S&P 500 Index ($SPX) (SPY) today is up +0.36%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.47%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.40%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Equity markets have turned cautious amid doubts that heavy AI spending will yield meaningful returns or that new AI tools will disrupt many sectors including finance, logistics, software, and trucking

    80% confidence

  • S&P earnings growth is expected to climb by +8.4% in Q4 2025, marking the tenth consecutive quarter of year-over-year growth

    80% confidence

  • Nvidia exited its equity investment in Applied Digital

    80% confidence

  • 75% of the 379 S&P 500 companies that have reported Q4 earnings beat expectations

    80% confidence

  • Wells Fargo Securities downgraded Knife River to underweight from equal weight with a price target of $81

    80% confidence

  • More than three-quarters of the S&P 500 companies have reported earnings results as Q4 earnings season nears its end

    80% confidence

  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings are expected to increase by +4.6%

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com